Medicine
Tazverik 200 mg tablet
Tazverik 200 mg tablet is a prescription medicine containing Tazemetostat for oral use, marketed by Epizyme, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
TAZVERIK is available in: Bottles of 240 tablets with a desiccant, NDC…
Key facts
- Active ingredient (INN)
- Tazemetostat
- Brand
- Tazverik
- Strength
- 200 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 240 tablets
- Marketing authorisation holder
- Epizyme
- Manufacturer
- Epizyme
- Origin register
- US FDA, United States
- Storage
- TAZVERIK is available in: Bottles of 240 tablets with a desiccant, NDC 72607-100-00 Do not store above 30°C (86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 January 2020
- Identifiers
- RxCUI 2274384, 2274390DailyMed set ID 7db07b5f-4e22-467c-9c0a-f830b08dbb1dNDC 72607-100Application NDA211723
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 240 tablet, film coated in 1 bottle | 72607-100-00 | Epizyme | 23 January 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 23 January 2020 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Tazemetostat is a methyltransferase inhibitor indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection, among other approved uses. MedsAcross supplies Tazemetostat for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about TazemetostatFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TAZVERIK prescribing information (Epizyme) · U.S. National Library of Medicine, DailyMed
Need Tazverik 200 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.